This trial is testing a flavored, orally-administered form of irinotecan (VAL-413) given with temozolomide to see if it is safe and effective for treating recurrent pediatric solid tumors, including neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma.
The primary treatment in this trial is VAL-413, given at 75 mg/m2/day. This treatment is free for patients. There is no placebo group in this trial; all patients will receive active treatment. VAL-413 has previously been approved by the FDA for a different condition.